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Lactose intolerance is a common disorder affecting an individual’s ability to digest lactose present in milk or any food product. 
Lactose intolerance is caused by the deficiency of β-galactosidase (lactase) in the digestive tract. Diagnosis of lactose intoler-
ance is not so simple and straightforward clinically. Many biochemical and genetic tests have been developed for the determina-
tion of lactose intolerance. Several case reports indicate wherein subjects have self-diagnosed being lactose intolerant. There 
is an emerging link of this disorder with human gene polymorphism, where genetic basis has been used as a diagnostic tool. 
The high prevalence of this condition among children and adults has compelled the production of lactose-free foods. Addition-
ally, external enzyme supplementation has been looked at as an alternative protective mechanism in lactose intolerant subjects. 
This review highlights the genetic variants of lactase polymorphism and theranostic (therapeutic and diagnostic) strategies for 
lactose intolerance. Biomed Rev 2014; 25: 35-44
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INTRODUCTION
Lactose is a disaccharide present in mammalian milk and is es-
sential for the nourishment of newborn infants. It is hydrolyzed 
by the intestinal brush-border enzyme, lactase, into absorbable 
sugars, namely glucose and galactose to provide energy. In 
most infants, intestinal lactase activity is maximal during the 
postnatal period. However, after 2–12 years of age, there oc-
curs a segregation into two distinct groups, viz, “lactase non-
persistence group” with low lactase activity (hypolactasia) and 
a “lactase-persistence group” of individuals who retain their 
neonatal level of lactase activity even in adulthood (1-3).
 Lactose intolerance is caused by the deficiency of 
β-galactosidase (lactase) in the digestive tract. The typical 
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clinical symptoms consist of abdominal pain and distension 
of gastrointestinal tract, borborygmi, and flatulence. Some-
times diarrhoea may occur from 30 minutes and 2 hours after 
the ingestion of lactose (4).  Lactase deficiency results in lack 
of absorption of non-digested lactose, which causes luminal 
water retention and leads to iso-osmolarity of chyme. Con-
sequently, excessive fluid retention causes abdominal pain, 
nausea, and diarrhoea. Bacterial fermentation of lactose in 
the distal small intestine and colon further aggravate these 
symptoms. 
 Because of the acute diarrhoeal condition that occurs after 
drinking milk, people who suffer from this disorder gener-
ally avoid a lactose-containing diet such as milk and milk 
products (5). Nevertheless, milk is calcium and nutrient-rich 
food and an important part of a healthy diet (6). Avoidance of 
milk during childhood is a significant risk factor for retarded 
growth and development as well as low bone density (7). 
Those who avoid milk, due to lactose intolerance, consume 
significantly less calcium and suffer from poorer health and 
bone formation, and higher risk of osteoporosis (7). Some 
studies have suggested that the prevalence of lactose intoler-
ance is a global issue. It is estimated that the worldwide popu-
lation incidence of this condition is around 30.5% in children 
of 11–13 years (8), and about 55.1% in Chinese adults (9). 
Also, high incidence of lactase deficiency has been reported 
among Hispanic people (50% to 80%), African-American 
and Ashkenazi Jewish population (60% to 80%), and is al-
most 100% in Asian and American Indian people (10).
 As summarized in Table 1, lactose intolerance is observed 
in various distinct forms such as congenital, primary and 
secondary. Congenital lactase deficiency is associated with 
the least lactase activity. Congenital hypolactasia is a single 
autosomal recessive disorder and is a extremely rare condi-
tion (11). Primary adult-type hypolactasia is an autosomal 
recessive condition, resulting from the physiological decline 
of lactase enzyme activity in the intestinal cells, and oc-
curs in a large proportion of individuals. A single nucleotide 
polymorphism, C ⁄T-13910, 14 kb upstream the lactase gene, 
has recently been correlated with lactase persistence⁄non 
persistence in several populations (12, 13). Secondary causes 
of hypolactasia, such as celiac disease, gastroenteritis and 
Crohn’s disease, may lead to transient lactase deficiency and 
Table 1. Types of lactase deficiencies and their associated risk factors (References cited are shown in brackets)
Type of lactase deficiency Risk factors / causes/triggers
Congenital  lactase deficiency This condition has been diagnosed in less than 50 people world-wide (15). It be-
comes apparent at birth with persistent diarrhoea soon after milk is introduced. 
These children otherwise have a normal intestinal mucosa (16).
Primary lactase deficiency It occurs when there is a gradual reduction in lactase production. It may not be-
come clinically evident until late adolescence (17). It’s prevalent in those geo-
graphical groups where the ancestors did not drink milk as a nutrient (15, 18).
Secondary lactase deficiency It occurs as a result of gastrointestinal illness that alters the nature of the gut 
mucosa (19). Cryptosporidiosis, giardiasis and other parasitic infections lead to 
lactose malabsorption; it is very common in the children with rotaviral diarrhoea 
(20). It may occur in association with celiac disease, Crohn’s disease and HIV (21, 
22). Secondary lactase deficiency may also occur due to certain drugs like tetracy-
cline and methotrexate that causes villous atrophy. Alcohol may initiate or worsen 
the lactose intolerance (18).
Developmental lactase deficiency Premature infants may experience this deficiency. However this condition is tem-
porary and improves as the intestinal mucosa matures (23).
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appearance of adverse abdominal symptoms (14).
 The present review highlights the genetic variants of 
lactase polymorphism and theranostic (therapeutic and 
diagnostic) strategies for lactose intolerance.
BIOCHEMISTRY AND GENETICS OF LACTASE
Lactase is located on the apical surface (glycocalix) of brush 
border enterocytes where it is anchored into the membrane 
by its C-terminal, with the bulk of the molecule projecting 
into the lumen of the gut (24). It is a large glycoprotein, with 
two active sites, that can catalyze the hydrolysis of a variety 
of β-glucosides, such as phlorizin, flavonoid glucosides (25), 
and pyridoxine-5’-β, -D glucoside (26), and β-galactosides 
in addition to lactose. Lactase is encoded by a single gene 
(LCT) which is approximately 50 kbp located on chromo-
some 2 (27, 28). The gene has 17 exons (27) and encodes an 
mRNA transcript for a preproprotein of 1927 aminoacid resi-
dues (29). This is composed of a putative signal peptide of 19 
aminoacid residues, a large pro-portion of 849 amino acids 
and a mature protein that contains two catalytic sites, and at 
the C-terminal, a membrane-spanning domain and short cy-
toplasmic domain. LCT shows a four-fold internal homology, 
which suggests that it arose by two duplication events (24). 
Pro-lactase is proteolytically processed to a smaller protein 
(30-32) and two of the four homologous regions occur in the 
cleaved pro-portion of the molecule, which does not have a 
catalytic function, but probably has a chaperone function, in 
that it seems to play a role in transporting the molecule to the 
cell surface (33-38). There is one active site in each of the 
domains of the mature protein. Although details have been 
disputed by some investigators, it is now considered that the 
active site at Glu1273 in domain III is responsible for hydro-
lysis of glucosides such as phlorizin, whereas the other in do-
main IV, at Glu1749, catalyzes the hydrolysis of galactosides 
such as lactose (39, 40).
 It has been reported that lactase is O-glycosylated through 
serines and threonines as well as N-glycosylated (through as-
paragine), and this glycosylation probably affects enzymatic 
activity as well as folding and intracellular transport (41). 
Lactase expression is restricted to the enterocytes of small 
intestine, at highest level being in the mid-jejunum (42). 
LACTOSE INTOLERANCE SYMPTOMATOLOGY
Gut related symptoms
Hypolactasia may not cause any discomfort unless lactose-
containing food is consumed. Colonic microflora ferment un-
digested lactose in the intestinal lumen, which leads to pro-
duction of short-chain fatty acids, hydrogen, carbon dioxide, 
and methane as by-products causing flatulence, bloating and 
abdominal pain. Undigested lactose acidifies the colon and 
increases the osmotic load, resulting in formation of foamy, 
voluminous and aqueous stools (43).  However, some pa-
tients can experience constipation due to decreased intestinal 
motility, possibly caused by production of methane (43).
Other symptoms 
The clinical presentation of lactose intolerance is not just 
restricted to gut symptoms. Other complaints such as head-
ache, vertigo, memory impairment, lethargy, muscle and 
joint pains, allergy, cardiac arrhythmia, mouth ulcers, and 
sore throat have been reported (4, 44). Colonic bacteria gen-
erate toxic metabolites by lactose fermentation such as acet-
aldehyde, ethanol, acetone, peptide and protein toxins, which 
can alter many cell signalling mechanisms and are possibly 
responsible for these symptoms (44). 
 There is a considerable individual variability in the sever-
ity of symptoms, depending upon the amount of lactose in-
gested and the patient’s ability to digest it. Factors contribut-
ing to this variability include osmolarity and the fat content 
of lactose-containing food, ability of colonic microflora to 
ferment lactose, gastric emptying rate, colonic water absorp-
tion capacity, intestinal transit time and individual perception 
of abdominal pain and discomfort (43, 45).
EMERGING LINKS WITH GENETICS: LACTASE PERSISTENT 
ALLELES AND LACTASE POLYMORPHISMS
As indicated above, the LCT gene is 49.3 kbp in length and 
is located on the long (q) arm of chromosome 2 at position 
21. It contains 17 exons and is translated into a 6 kb tran-
script (27-29). Individuals with hypolactasia and lactase per-
sistence have identical coding sequences, except for a few 
silent mutations; hence, both lactases are identical (46). Two 
variants were found to be associated with lactase persistence: 
A polymorph variant, LCT-13910C.T, in intron 13 of the 
MCM6 gene that is 13 910 bp from the initiation codon of 
LCT, while the LCT-22018G, a variant in intron 9 of MCM6 
gene upstream of the LCT locus 22,018 bp was associated 
(1, 2, 47).This association was confirmed in a study of DNA 
collected from subjects of Finnish, South Korean, Italian, 
German, French, or Caucasian or African-North-American 
descent (1,47). Both genotypes of LCT-13910CT and LCT-
13910TT were associated with the lactase-persistence pheno-
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type, indicating that the presence of one single lactase-persis-
tence allele in the heterozygous state has a dominant effect, 
rendering the person a lactose digester (48). 
PROMOTOR SEQUENCE STUDIES
Functional in vitro studies of these polymorphic alleles have 
shown that LCT-13910T (1, 49, 50), LCT-13907G, LCT-
13915G, and LCT-14010C act as enhancers of the LCT 
promoter (51).  These effects are most likely mediated by 
the Oct-1 transcriptional factor binding site in the variant 
enhancer and by HNF1α binding in the LCT promoter (49, 
52). LCT gene regulation of lactase-persistence alleles oc-
curs at the transcriptional level. LCT mRNA levels, which 
are distinguished by polymorphic markers in the coding 
region of LCT, were several times higher in individuals 
with LCT-13910T/-22018A alleles than in individuals with 
LCT-13910C/-22018G alleles (1). It has also been generally 
agreed that nonpersistent individuals have lower levels of 
lactase mRNA [53-55].
 Numerous transcription factors (Cdx2, GATA-4, GATA-5, 
GATA-6, and HNF1α) activate the LCT promoter in intes-
tinal cell culture at the -100 to -20 bp binding site regions 
of LCT which are repressed by PDX-1 (1). Mutation of the 
PDX-1 binding site does not prevent LCT promoter repres-
sion, which suggests that PDX-1 might function by binding 
to another DNA binding site or by inhibiting other transcrip-
tional factors. PDX-1 over expression resulted in strong re-
pression of Cdx2 and HNF1α activation of the LCT promoter 
(1). However, the exact mechanism for down regulation of 
LCT after weaning still remains unknown.
CONGENITAL LACTASE DEFICIENCY
While secondary loss of lactase in children is a frequent prob-
lem, resulting from viral infection and allergy (56), true con-
genital deficiency of lactase is very rare indeed. Congenital 
lactase deficiency is one of the severe gastrointestinal disor-
ders characterized by watery diarrhoea shortly after the first 
feed with breast milk or lactose containing formulas (57). It 
is a rare autosomal disorder which occurs due to mutations 
in the coding regions of lactase, LCT gene. The LCT gene 
consists of 17 exons encoding 1927 amino acids compris-
ing four homologous domains I-IV. Domain IV harbours the 
lactase activity mutation in exon 9 and is responsible for the 
truncation of lactase. One such case was recently reported 
in a Japanese female infant who had two mutations in the 
LCT gene in a heterozygous form: c.4419C> G (p.Y1473X) 
in exon 10 and c.5387 delA (p.D1796fs) in exon 16, these 
mutations occurred in domain IV and was considered caus-
ative for congenital lactase deficiency (58).
FALLACIES FOR SELF-DIAGNOSIS OF LACTOSE INTOLERANCE 
Due to an increased public awareness about the prevalence 
of lactose intolerance, there have also been several misunder-
standings about self-diagnosis (59). In addition, there is also 
a little understanding that lactose maldigestion (incomplete 
lactose digestion due to low levels of lactase) is not synony-
mous with lactose intolerance (symptoms such as bloating, 
cramps and diarrhoea that may or may not occur in associa-
tion with undigested lactose in the intestinal tract). Many 
studies have identified that the majority of those with lactose 
maldigestion do not experience the symptoms of lactose in-
tolerance after consuming moderate quantities of lactose (60-
70), and consequently avoid the lactose containing foods. 
One such food is milk, which is the richest source of calcium, 
vitamins, fatty acids, and low intake of milk can lead to seri-
ous health complications, including chronic disease like os-
teoporosis (59). On the contrary, it has also been reported that 
consuming dairy foods may actually contribute to improve 
the tolerance to lactose. Thus, individuals with self-reported 
lactose intolerance are unlikely to meet the appropriate lev-
els for calcium from food sources alone. Dietitians and other 
health professionals can play an important role in informing 
these individuals about how to include lactose-containing 
foods without experiencing adverse symptoms, as well as 
providing information on other food sources of calcium, and 
further if needed, advice on appropriate supplementations.
IMPLICATIONS OF LACTOSE INTOLERANCE AND OTHER 
DISEASES
In addition to being a major cause of inconvenience in it-
self, lactose intolerance could be associated with other health 
disorders like cystic fibrosis, an autosomal recessive disor-
der characterized by the loss of function of the cystic fibro-
sis transmembrane conductance regulator (CFTR) (71, 72). 
This occurs due to more than 1700 different mutations in the 
CFTR gene, the most common of which is the loss of phe-
nylalanine at the 508 position of the CFTR protein resulting 
in its misfolding, a faulty posttranslational processing and 
endoplasmic reticulum regulated degradation (73). Reduced 
bone mineral density is a common malady affecting cystic 
fibrosis patients. Since, meat cannot by itself serve as a nu-
tritional source (due to absence of pancreatic elastase-1 in 
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pancreatic supplements, an enzyme required to digest elas-
tin fibres in meat) for exocrine pancreatic insufficient cystic 
fibrosis patients, the only alternative is dairy products (71). 
Although not typical for cystic fibrosis, lactose intolerance 
can hamper dairy product consumption and fail to help cys-
tic fibrosis patients to increase their bone mineral density in 
severe cases.
 Lactose intolerance could also be associated with epilep-
sy, which affects about 45 million people across the globe 
(74-76). Neural cells contain glycosphingolipids whose bio-
synthesis requires galactose which is derived from lactose 
and other carbohydrates. Lactose intolerance impairs the pro-
duction of galactose which could lead to malfunctioning of 
neurons resulting in epileptic episodes (77).
DIAGNOSIS OF LACTOSE INTOLERANCE
Previously, the most reliable method available for detecting 
lactose intolerance was a direct biochemical assay of lactase 
activity from a jejunal sample which was performed with a 
glucose oxidase reagent, that detects glucose liberated from 
lactose, with a cut off value of 10 U/g protein (1,2).  However 
due to the invasiveness of jejunal biopsy, this method was 
then replaced by endoscopic duodenal biopsy (78,79).  
 Lactose tolerance tests have been developed to confirm the 
ability of intestinal lactase to hydrolyze lactose so as to avoid 
intestinal biopsies. In this technique, blood glucose levels 
are measured before and after an oral load of lactose at pre-
specified time intervals, with a maximum rise of 20 mg/dL, 
indicating lactose tolerance (80). Oral ethanol administration 
before lactose load is used to inhibit galactose metabolism 
for the determination of the blood maximum rise of glucose 
(at least 20 mg/dL) and galactose (at least 10 mg/dL), thereby 
indicating lactose tolerance. Thus, galactose concentration in 
combination with glucose concentration improves the corre-
lation with jejunal lactase activity than using only glucose 
maximum rise after lactose load (81).
 Despite of all the indirect lactose tolerance tests current-
ly available, breath hydrogen concentration after ingestion 
of 50 g of lactose was considered the most suitable test for 
population screening for lactase deficiency (82). However, 
the use of the 50 g lactose dose has been criticized, because 
it is equivalent to 4–5 cups of milk, an amount that is ideally 
far more than an individual can usually ingest at one time, so 
an oral load of 25 g may be considered a more appropriate 
amount, with high sensitivity and specificity (80,83).
 Interestingly, the discovery of lactase-persistence al-
leles resulted in the advent of genetic tests for diagnosis of 
lactase non-persistence by polymerase chain reaction re-
striction fragment length polymorphism (84-86), real-time 
polymerase chain reaction [87-89], and pyrosequencing tech-
nology (90). Compared with the lactose hydrogen breath test, 
the genetic test has numerous advantages such as it is simple, 
non-invasive, and more comfortable examination that does 
not provoke symptoms of lactose intolerance and is less cum-
bersome (85). However, other polymorphic variants in Euro-
peans (LCT-13914G.A)50 and in African and Arab popula-
tions (LCT-13907C.G, LCT-13913T.C, and LCT-13915T.G, 
close to LCT-13910C.T,) affect the diagnostic accuracy of 
LCT-13910C.T typing by altering the melting profiles of the 
real-time polymerase chain reaction kit [89]. The reverse-
hybridization strip assay based on multiplex DNA amplifica-
tion and ready-to-use membrane test strips that detect LCT 
polymorphic variants (-13907C.G, -13910C.T, -13913T.C, 
-13914G.A, -13915T.G, and -22018G.A) and inevitably rep-
resents a reliable tool for genetic diagnosis of lactase non-
persistence helps in overcoming the interference of different 
melting profiles of the real-time polymerase chain reaction 
kit by the other polymorphic variants (91). The genetic test 
provides a more direct result, i.e., a hypolactasia or lactase 
persistence genotype, whereas interpretation of the lactose 
breath test depends on several variants such as the cut off 
level, dose of lactose given, and duration of the test and age 
of the individual, and is also expensive. 
NOVEL TREATMENT INTERVENTIONS FOR MANAGEMENT OF 
LACTOSE INTOLERANCE
The initial recommendation for management of lactose intol-
erance is to aim for remission of symptoms through tempo-
rary avoidance of milk and dairy products. Most individuals 
with lactose malabsorption can tolerate up to 12 g of lactose 
without significant symptoms. After the initially restricted 
diet, lactose should be gradually reintroduced until the pa-
tient’s threshold for symptoms is reached (92). The main 
pharmacological measures include lactase supplements, lac-
tose-hydrolyzed or lactose-reduced milk, probiotics (93), and 
colonic adaptation. 
NON-LACTOSE INFANT FORMULAS
Infants who cannot tolerate any lactose may only be treated 
by excluding lactose from diet. This could be achieved by us-
ing lactose-free infant formulas or incubating feeds with the 
enzyme lactase which can break the sugar into its component 
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parts. In case of primary lactose intolerance where the degree 
of lactase deficiency varies, the use of lactose-free formula 
may help to relieve symptoms. In lactose-free formula, the 
carbohydrate source is glucose rather than lactose, therefore 
these milk products have a greater potential to cause den-
tal caries. This is because lactose is a non-cariogenic sugar 
whereas glucose is cariogenic (94).
 Soy-based infant formulas have been often preferred to 
lactose-free formula. However, they may not be safe because 
contain phytoestrogens; note, soy formulas are no more in us-
age for infants. A recent report suggests that phytoestrogens 
in soy infant formulas are capable of inhibiting the action of 
an enzyme involved in iodination of thyroxine (thyroid per-
oxidase, TPO) through competitive inhibition (95). It has not 
yet clearly established that the levels of free phytoestrogen 
in infants’ plasma are sufficient to significantly inhibit TPO. 
Hence, the clinical significance of phytoestrogen consumption 
in the presence of adequate iodine intake still remains unclear.
ENZYME THERAPY: ENDOGENOUS β-GALACTOSIDASE TO 
ALLEVIATE LACTOSE INTOLERANCE 
In addition to decreasing the lactose concentration in milk 
products, there have been several techniques that have been 
used to produce low-lactose milk, such as β-galactosidase 
enzymes hydrolysis techniques or combinative techniques 
with ultrafiltration and enzymes hydrolysis (96, 97). Howev-
er, they have also been known to alter the quality of the milk 
products and their commercial value (98). Enhancing the in-
testinal β-galactosidase activity of lactose intolerant subjects 
has gained more importance. Exogenous β-galactosidase 
was usually prescribed for lactose intolerant subjects. How-
ever, most of the supplemental β- galactosidase displayed 
poor stability in human gut. Interestingly, the endogenous 
β-galactosidase expressed in intestinal microbes has been 
reported to help humans in lactose usage (99), and is one 
of the promising treatment strategies, since it is associated 
with the promotion of beneficial microorganism in the gut 
(100). Therefore, the enhancement of β-galactosidase in the 
intestinal microflora of humans together with selected pro-
biotics may be a promising approach in lactose intolerance 
management. An evidence to this fact was provided by a re-
cent in vivo study conducted to evaluate the alleviation of 
lactose intolerance symptoms in post-weaning Balb/c mice, 
which were orally administered with 1×106 CFU or 1×108 
CFU of L. lactis MG1363/FGZW daily for 4 weeks before 
lactose challenge. It was observed that in comparison with 
naïve mice, the mice administered L. lactis MG1363/FGZW 
showed significant reduction of diarrhea symptoms accompa-
nied by lesser weight of total feces within 6 h post-challenge 
and suppressed intestinal motility after lactose challenge.
CONCLUSION
We have highlighted the genetic variants of lactase polymor-
phism and theranostic strategies for lactose intolerance. A 
significant progress has been made in our understanding of 
lactose intolerance. Management of lactose intolerance has 
improved over the years with the introduction of newer and 
better options which help to bypass the inevitable pitfalls of 
simple lactose avoidance. There is no single gold standard 
test available for the diagnosis of lactose intolerance. The 
lactose breath test, although considered the best method may 
be influenced by several factors. Genetic testing has been 
a new tool for the diagnosis of hypolactasia/lactase persis-
tence, but may not detect all the single nucleotide polymor-
phisms associated with this disorder. It appears that up to 
12 g of lactose is well tolerated by lactase non-persistence 
individuals, which may negate the need for restrictions on 
lactose-hydrolyzed milk, fermented and matured milk prod-
ucts, hence preventing any subsequent deleterious effects on 
bone mass density. 
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